cancer

medicine

Scientists at Yale School of Medicine design a virus to treat ovarian cancer

Marisa Peryer, Senior Photographer

A new Yale study showed that certain genetically modified viruses can cure ovarian cancer in mice. It may be of use in the treatment of ovarian cancer in humans.

Researchers at the Yale School of Medicine have tested a chimeric virus — containing genes from two different viruses — that can selectively infect and kill ovarian cancer cells in mice. Their findings represent a potential breakthrough in the long-term treatment of ovarian cancer in humans. The study was published in the journal Virology on Nov. 12, two weeks after the death of the paper’s lead author Anthony Van den Pol, former professor of neurosurgery and psychiatry at Yale.

“Every year, around 20,000 women are diagnosed with ovarian cancer, which is a smaller number compared to cancer types such as breast cancer,” said Gil Mor, the scientific director of the C.S. Mott Center for Human Growth and Development at Wayne State University and a co-author of the paper. “However, unfortunately only around 4,000 of those women can survive the disease.”

The main reason behind the lethality of ovarian cancer is the lack of treatments preventing the recurrence of the disease. In 80 percent of cases, patients who respond positively to chemotherapy still experience a return of the disease, according to Mor. He explained that once the cancer comes back and begins to spread, there is little that doctors can do.

The inspiration for the study was born out of a collaboration between Van den Pol and Mor many years ago, when they worked in adjacent labs at the Yale School of Medicine. Van den Pol, a research scientist in the Neurosurgery Department, had concentrated his research on the long-term treatment of brain tumors. Mor, on the other hand, had been working on treatments for ovarian cancer. The two scientists decided to collaborate to find an alternative treatment for ovarian cancer through oncolytic viruses, which selectively infect and kill cancer cells.

In the experiment’s in vitro phase, in which the research takes place in laboratory tubes or petri dishes without a living component, researchers made a virus called Lassa-VSV in the laboratory. Lassa-VSV consists of three parts: the Lassa virus, the vesicular stomatitis virus, or VSV, and a fluorescent label to facilitate tracing, according to Nazli Albayrak, a scientist who was involved in the in vitro phase. During this phase, the team infected different ovarian cancer cell lines, eventually choosing the ones that were infected most frequently to proceed with the research. 

Then, after deciding on the cell line, the team injected tumor cells into the bodies of the mice, the paper explains. As the tumor cells began to replicate, the team then injected the Lassa-VSV virus into the tumor clusters. They observed that the virus infected the tumor cells very effectively yet did not harm the healthy cells

Read More
medicine

Worldwide Cancer Molecular Diagnostics Industry to 2025 – Personalized Medicine and Pharmacogenomics are Driving Growth

DUBLIN, Dec. 1, 2020 /PRNewswire/ — The “Molecular Diagnostics for Cancer – Markets, Strategies and Trends. Forecasts by Cancer Type, Including Companion Dx and by Country with Executive and Consultant Guides and COVID-19 Pandemic Recession Forecast Revisions. 2021 to 2025” report has been added to ResearchAndMarkets.com’s offering.

A market with fundamental growth factors is impacted by the COVID-19 Pandemic. Molecular Diagnostics for Cancer is positioned to directly benefit from the explosion in genomics knowledge but shifting resources to deal with the COVID emergency may interrupt growth. Learn all about it in this new report. the publisher includes a special segment, Cancer Companion Diagnostics, a new segment of the market that is reshaping the industry. And now over 130 companies are profiled. A range of dynamic trends are pushing market growth and company valuations.

Trends like:

  • personalized medicine
  • pharmacogenomics
  • liquid biopsy
  • emergence of new economies with large markets
  • greater understanding of the role of genetic material in Disease and Health

Working against this dynamic market are the forces of the COVID Driven Recession. The publisher’s latest numbers factor in the different COVID forces, their timing, and their effect on growth.

Exciting technical developments especially in the area of pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage.

This report provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2020 United States Medicare Fee Payment Schedules to help understand test pricing in detail. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions.

Assistance in providing specific growth and market size estimates for new technology tests is normally provided without additional charges. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth. Again, assistance in using the information is normally provided without additional charges, please enquire further for more information.

The report includes detailed breakouts for 18 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasers of the report.

Key Topics Covered:

1. Introduction and Market Definition

2. Market Overview
2.1 Market Participants
2.1.1 Academic Research Lab
2.1.2 Diagnostic Test Developer
2.1.3 Genomic Instrumentation Supplier
2.1.4 Pharmaceutical/Reagent Supplier
2.1.5 Independent Testing Lab
2.1.6 Public National/regional lab
2.1.7 Hospital lab
2.1.8 Physician Lab
2.1.9 Audit Body
2.1.10 Certification Body
2.2 Market Segments
2.2.1 Traditional Market Segmentation
2.2.2 Laboratory Focus and Segmentation
2.3 Industry Structure
2.3.1 Hospital Testing Share
2.3.2 Economies of Scale
2.3.3 Physician Office Lab’s
2.3.4 Physician’s and POCT

3. Market Trends
3.1 Factors Driving Growth
3.1.1 New Diagnostics Create New Markets
3.1.2 New Roles for Diagnostics
3.1.3 Longevity and Outcomes
3.1.3 Expanding the Pharmaceutical Toolbox
3.1.4 Regulatory Retreat
3.2 Factors Limiting Growth
3.2.1 Falling Prices
3.2.2 Lower Costs
3.2.3 COVID Pandemic
3.2.4 Wellness has a Downside
3.3 Instrumentation and Automation
3.3.1 Instruments Key to Market Share
3.3.2 Bioinformatics Plays a Role

Read More
medicine

Worldwide Cancer Molecular Diagnostics Industry to 2025

DUBLIN, Dec. 1, 2020 /PRNewswire/ — The “Molecular Diagnostics for Cancer – Markets, Strategies and Trends. Forecasts by Cancer Type, Including Companion Dx and by Country with Executive and Consultant Guides and COVID-19 Pandemic Recession Forecast Revisions. 2021 to 2025” report has been added to ResearchAndMarkets.com’s offering.

A market with fundamental growth factors is impacted by the COVID-19 Pandemic. Molecular Diagnostics for Cancer is positioned to directly benefit from the explosion in genomics knowledge but shifting resources to deal with the COVID emergency may interrupt growth. Learn all about it in this new report. the publisher includes a special segment, Cancer Companion Diagnostics, a new segment of the market that is reshaping the industry. And now over 130 companies are profiled. A range of dynamic trends are pushing market growth and company valuations.

Trends like:

  • personalized medicine
  • pharmacogenomics
  • liquid biopsy
  • emergence of new economies with large markets
  • greater understanding of the role of genetic material in Disease and Health

Working against this dynamic market are the forces of the COVID Driven Recession. The publisher’s latest numbers factor in the different COVID forces, their timing, and their effect on growth.

Exciting technical developments especially in the area of pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage.

This report provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2020 United States Medicare Fee Payment Schedules to help understand test pricing in detail. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions.

Assistance in providing specific growth and market size estimates for new technology tests is normally provided without additional charges. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth. Again, assistance in using the information is normally provided without additional charges, please enquire further for more information.

The report includes detailed breakouts for 18 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasers of the report.

Key Topics Covered:

1. Introduction and Market Definition

2. Market Overview
2.1 Market Participants
2.1.1 Academic Research Lab
2.1.2 Diagnostic Test Developer
2.1.3 Genomic Instrumentation Supplier
2.1.4 Pharmaceutical/Reagent Supplier
2.1.5 Independent Testing Lab
2.1.6 Public National/regional lab
2.1.7 Hospital lab
2.1.8 Physician Lab
2.1.9 Audit Body
2.1.10 Certification Body
2.2 Market Segments
2.2.1 Traditional Market Segmentation
2.2.2 Laboratory Focus and Segmentation
2.3 Industry Structure
2.3.1 Hospital Testing Share
2.3.2 Economies of Scale
2.3.3 Physician Office Lab’s
2.3.4 Physician’s and POCT

3. Market Trends
3.1 Factors Driving Growth
3.1.1 New Diagnostics Create New Markets
3.1.2 New Roles for Diagnostics
3.1.3 Longevity and Outcomes
3.1.3 Expanding the Pharmaceutical Toolbox
3.1.4 Regulatory Retreat
3.2 Factors Limiting Growth
3.2.1 Falling Prices
3.2.2 Lower Costs
3.2.3 COVID Pandemic
3.2.4 Wellness has a Downside
3.3 Instrumentation and Automation
3.3.1 Instruments Key to Market Share
3.3.2 Bioinformatics Plays a Role

Read More
medicine

How has medicine changed in the past 20 years? A look at dementia, cancer care and chronic disease

The 21st century began with the first draft of the human genome, and with it, the promise of immense new powers to treat, prevent and cure disease.

In high-income countries like Australia, rates of heart disease were falling, and life expectancy was rising.

Over the past two decades, lots has changed about the factors that affect our health, wellbeing and how long (and well) we live.

So what do we know now that we didn’t then, and how far have we come?

As part of Radio National’s Big 20 series, Dr Norman Swan speaks to three leaders in their field to find out what’s happened in dementia research, cancer care and chronic disease over the last 20 years.

Chronic disease has been getting worse

Dr Norman Swan talks to Professor Chris Murray, director of the Institute of Health Metrics and Evaluation at the University of Washington.

Dr Swan: Take us back to the year 2000. What was the pattern of disease?

Professor Chris Murray: In the year 2000, right before the big push globally on reducing health problems in low income settings, we were pretty much nearing the peak of the HIV epidemic and, particularly in sub-Saharan Africa, we still had a very large number of deaths under age five — 12 million or so a year.

We hadn’t yet had the big efforts to control malaria. And many middle-income countries were right in that transition from a profile of disease burden dominated by infectious diseases and starting that shift towards cancer, heart disease, chronic kidney disease.

Listen to the podcast

Hear the full interviews with Dr Norman Swan on the Health Report podcast.

Read more

In the high-income world — Australia, Europe, North America — the [disease burden] looked pretty similar. It was already heavily dominated by heart disease and cancer, chronic kidney disease, but there was less obesity back then, there was less diabetes, and we were still back in the heyday of heart disease coming down pretty rapidly.

Dr Swan: What has happened in the two decades since?

Professor Murray: We’ve seen really dramatic progress bringing down child death rates.

In a place like Niger in West Africa, the improvements are just spectacular. You’ve probably halved child death rates in that period … bringing [it] down below the 5 million mark because of antiretrovirals for HIV.

There has been real progress on controlling malaria because of bed-net programs. So just lots of progress racked up, until COVID, on a number of fronts in the low-income world.

Then at the other end of the spectrum in the high-income world, we’ve seen heart disease progress slow, and in some places reverse.

We’ve seen this steady rise of obesity and bringing with it diabetes, high blood sugar, bringing up blood pressure levels in some countries, despite all the therapies that exist for them.

In the middle-income world we’ve seen progress but we’ve seen the rise of ambient air pollution in the last two decades. It’s becoming a bigger and

Read More
medicine

Philip Sharp: Senior with cancer chooses between medicine and food – Entertainment – Austin American-Statesman

Philip Sharp is battling a case of the sniffles, but, beyond that, he says he’s feeling good.

He’s got his cat of 13 years, Sweetheart. He’s talked to his daughter, Jessica, recently, and the PBS signal is still coming in strong.

You’d never know that days earlier the soft-spoken Sharp had finished his most recent round of chemotherapy treatment.

Sharp is not prone to self-pity or asking for much help. On the day in question, as he stands in his modest apartment talking to me via a Zoom connection facilitated by his case manager with Family Eldercare, Sharp expresses gratitude for the assistance he’s received and the minimal side effects of the treatments for a cancerous lesion recently removed from his bladder. He also is slated to undergo gallbladder removal surgery in the spring.

While his polite demeanor and tender nature serve as no sign for concern, the truth is that recently the 65-year-old, who lives alone with Sweetheart, was dangerously close to having to make this choice: paying for medicine or paying for food.

On lean days like those, Sharp turned to a simple diet of canned beans. You’d be hard-pressed to get him to complain about it. He will talk about food, however. The things he loves. Like a pizza loaded with meat. Tacos. And the Hungry Man meals that Jessica delivered to him recently.

Sharp has lived in Austin since 1998, and while he’s had a long tenure in town, his social circle remains limited. He turns to online chat rooms to make friends with folks his age and talk about their lifestyles, and finds joy in watching PBS shows about American history and science.

“I’m not a real socialite,” Sharp says.

Sharp, who successfully manages schizoaffective disorder through a medication regimen, studied chemistry in college. The jazz flutist also studied music, forestry and computer science but eventually cut short a college education that included stints at Stephen F. Austin University and what is now Texas State University.

“It was all so boring; I couldn’t take it anymore,” Sharp says dryly.

After a period of homelessness following a divorce and car accident, Sharp received assistance from Family Eldercare, the organization that nominated him for Season for Caring, which helped stabilize his living situation.

The nonprofit has assisted Sharp, who lives off of disability benefits, with the stress of managing his finances and staying on top of his medical appointments and mounting bills. For that, Sharp is very grateful.

“It makes me feel very comforted to know somebody is going to be there,” Sharp says.

More Season for Caring.

Source Article

Read More
medicine

AI-based earlier medicine development leveraging TWCC HPC to aid cancer prediction research

AI-based earlier medicine development leveraging TWCC HPC to aid cancer prediction research

Artificial Intelligence (AI) is shaping the future of global medical industries. The practice of medicine is changing with the development of AI methods of machine learning. As the increasing accuracy of predictive medicine, AI technology, based on analyzing patient’s medical records, is entailing predicting the probability of disease in order to either further diagnosis of disease allowing for the estimation of disease risks or significantly decrease the cost to deal with its impact upon the patient. The AI based prediction medicine is a new type of earlier medicine

Hsuan-Chia Yang, assistant professor of the Graduate Institute of Biomedical Informatics, Taipei Medical University, explains Prediction of Principle Health Threat (PROPHET) project. Led by Dr. Li Yu-Chuan, a pioneer of AI in Medicine and Medical Informatics Research, earlier medicine for fatal diseases is leveraging AI technology and data mining systems to provide a personal, real-time, accurate and manageable healthcare program. The PROPHET project provides the prediction of cancer risks and boosts the new business opportunity of start-ups. Taiwan Ministry of Science and Technology provides the funding support for this kind of projects.

Taking breast cancer detection as an example, there are 5 persons confirmed as positive out of every 1000 people screening. Applying the AI earlier medicine perdition method, the effective rate will be reduced to 5 confirmed out of 233 people check. There are 77% saving of breast cancer earlier diagnosis. The saved cost is obvious.

The basic of PROPHET project is making AI Bio-maker model using AI technology to screen cancer and provide the prediction. Transforming the patient medical records to time matrix data diagrams, the skill is setting to predict 10 kinds of cancer risks after one year time frame based on sequential medical records to develop a prediction model. Each prediction of various cancers could reach 85% AUROC (Area under the receiver operating characteristic) curves. Taiwan Healthcare insurance program preserves every citizen’s healthcare digital records of treatments and medicine usage. PROPHET takes this strength to analyze three-year personal data records to predict the cancer risks of next 12-month. These lower cost AI-based cancer predictions allow healthcare professions to participate in the decision about whether or not it is appropriate testing or detection priority for patients.

From the technical point of view, the dynamic prediction value of personal diseases is a time-dependent scenario. The time matrix combined with personal medicine usage records and various diseases could make a two dimensional health diagram. The vertical axis is thousands of variables including medicine usage, set of medical signs and symptoms. The horizontal axis is time listings based on week or month. There are about 250 thousand health diagrams to use in the AI training process to get effective prediction AI models. After requiring repeat fine-tuning in training new AI models of each cancer, it can be derived effective prediction models based on above AI Bio-marker.

However, the huge compute power to perform these AI training tasks requires huge support

Read More
medicine

AccessHope and Northwestern Medicine Announce Novel Collaboration to Expand Nationwide Access to Best-in-Class Cancer Expertise

DUARTE, Calif. & CHICAGO–(BUSINESS WIRE)–On the heels of AccessHope’s national launch in October, the wholly owned subsidiary of City of Hope today announced it has joined forces with Northwestern Medicine to provide specialized cancer expertise to help more people achieve the best possible cancer outcomes. This novel collaboration brings two National Cancer Institute-designated comprehensive cancer centers together, enabling some of the country’s most sought-after specialists to offer expertise that can improve care, experience, outcomes and value for patients in the treatment of complex cancers.

“The NCI designation represents an elite group of cancer centers recognized for delivering high-quality clinical care, superior outcomes and outstanding patient experiences,” said AccessHope CEO Mark Stadler. “We’re honored to have Northwestern Medicine join City of Hope in the AccessHope program.”

The collaboration, which expands the current City of Hope network to now include experts from Northwestern Medicine, comes at a crucial time considering that COVID-19 has shown to have impacted cancer diagnosis, care and treatment. “COVID-19 has resulted in the number of cancer screenings and resulting diagnoses dropping significantly over the last several months,” noted Stadler. “AccessHope anticipates that as a result, cancer diagnoses may come later, when cancer has progressed or is at a more advanced stage, making it even more vital for individuals to receive an expert review of their case and start on the right course of treatment the first time.” City of Hope recognized the tremendous benefit to cancer patients of reimagining how they can receive the most innovative care available as close to home as possible. Demand from employers across the country led City of Hope to establish AccessHope. Today, AccessHope serves approximately 1.95 million members who have its cancer support services through 34 employers including 11 Fortune 500 companies.

AccessHope’s collaboration with Northwestern Medicine furthers its commitment to optimizing care for people facing cancer, regardless of their location. Through an employer health care benefit, employees of AccessHope clients who are diagnosed with cancer and their local treating oncologist can benefit from the expertise of specialists knowledgeable in the latest cancer discoveries for review of diagnosis, treatment plan and precision medicine opportunities, as well as clinical trial information and support services, without ever needing to leave their community.

“We believe access to the expertise we have at Northwestern Medicine and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University should not be limited by geography,” said Dean M. Harrison, president and chief executive officer, Northwestern Memorial HealthCare. “Through this collaboration, AccessHope members will benefit from the knowledge and experience of our world-class physicians and the latest in cancer research and treatment options.”

Top Ten Cancer Hospital Increases Remote Support Footprint

Northwestern Medicine is a nationally recognized health system that provides world-class compassionate care. Backed by Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Northwestern Memorial Hospital is ranked No. 8 in the nation for cancer care by U.S. News and World Report, 2020 – 2021. The Lurie Cancer Center is part of a select group of

Read More
medicine

AccessHope and Northwestern Medicine Announce Novel Collaboration to Expand Nationwide Access to Best-in-Class Cancer Expertise – Press Release

DUARTE, Calif. & CHICAGO–(Business Wire)–On the heels of AccessHope’s national launch in October, the wholly owned subsidiary of City of Hope today announced it has joined forces with Northwestern Medicine to provide specialized cancer expertise to help more people achieve the best possible cancer outcomes. This novel collaboration brings two National Cancer Institute-designated comprehensive cancer centers together, enabling some of the country’s most sought-after specialists to offer expertise that can improve care, experience, outcomes and value for patients in the treatment of complex cancers.

“The NCI designation represents an elite group of cancer centers recognized for delivering high-quality clinical care, superior outcomes and outstanding patient experiences,” said AccessHope CEO Mark Stadler. “We’re honored to have Northwestern Medicine join City of Hope in the AccessHope program.”

The collaboration, which expands the current City of Hope network to now include experts from Northwestern Medicine, comes at a crucial time considering that COVID-19 has shown to have impacted cancer diagnosis, care and treatment. “COVID-19 has resulted in the number of cancer screenings and resulting diagnoses dropping significantly over the last several months,” noted Stadler. “AccessHope anticipates that as a result, cancer diagnoses may come later, when cancer has progressed or is at a more advanced stage, making it even more vital for individuals to receive an expert review of their case and start on the right course of treatment the first time.” City of Hope recognized the tremendous benefit to cancer patients of reimagining how they can receive the most innovative care available as close to home as possible. Demand from employers across the country led City of Hope to establish AccessHope. Today, AccessHope serves approximately 1.95 million members who have its cancer support services through 34 employers including 11 Fortune 500 companies.

AccessHope’s collaboration with Northwestern Medicine furthers its commitment to optimizing care for people facing cancer, regardless of their location. Through an employer health care benefit, employees of AccessHope clients who are diagnosed with cancer and their local treating oncologist can benefit from the expertise of specialists knowledgeable in the latest cancer discoveries for review of diagnosis, treatment plan and precision medicine opportunities, as well as clinical trial information and support services, without ever needing to leave their community.

“We believe access to the expertise we have at Northwestern Medicine and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University should not be limited by geography,” said Dean M. Harrison, president and chief executive officer, Northwestern Memorial HealthCare. “Through this collaboration, AccessHope members will benefit from the knowledge and experience of our world-class physicians and the latest in cancer research and treatment options.”

Top Ten Cancer Hospital Increases Remote Support Footprint

Northwestern Medicine is a nationally recognized health system that provides world-class compassionate care. Backed by Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Northwestern Memorial Hospital is ranked No. 8 in the nation for cancer care by U.S. News and World Report, 2020 – 2021. The Lurie Cancer Center is part of a select group of NCI-designated comprehensive

Read More
medicine

Dr Sibel Blau Discusses the Importance of Precision Medicine for Cancer Practices

The Quality Cancer Care Alliance is focusing on 2 major topics: value-based care and innovation, and precision oncology is the intersection of those 2 issues, said Sibel Blau, MD.

The Quality Cancer Care Alliance (QCCA) is focusing on 2 major topics: value-based care and innovation, and precision oncology is the intersection of those 2 issues, said Sibel Blau, MD, medical oncologist, Northwest Medical Specialties, and president and CEO of QCCA.

Transcript

QCCA’s annual leadership summit kicked off with 2 sessions on precision medicine. Why is that topic so important to cancer practices right now?

Because it just fits with the value-based care mentality. I mean, we are, the QCCA network is focusing on 2 major topics, although we have other goals together. But 1 is the research network and bringing clinical trials—and every kind of trial, not just the traditional trials—every kind of research to our patients so that we can contribute to that innovation and give access to treatment with the new drug development our patients.

The other thing is the value-based care. So when you put those 2 together, and when you look at the precision medicine definition, and what we heard from our speakers last week, that it is not just genomic testing, it’s all about everything from diverse patient populations, to economics, to testing, to data-sharing platforms or data tools, and all of it together to be able to bring it into the patient. The talk about the right patient, the right time, and right place, and we have to provide the right care for the patient. And in order to do that, you have to look at it from a global perspective.

So, we thought when we were trying to bring our thoughts together, “what should be the theme of this meeting?” I think precision medicine is what we are trying to do in our practices in our daily practices and bring a bigger, broader perspective of precision medicine that fits with value-based care and research.

Source Article

Read More
medicine

Single mum with cancer promises daughter, 6, ‘magic medicine will make mummy better’

A solo mum has promised her young daughter ‘magic medicine will make mummy better’ after being diagnosed with breast cancer at just 40.

Melissa Lomas, of Poynton, Cheshire, is fundraising for a wig so she can keep her promise to her six-year-old daughter, Scarlett.

After being diagnosed with ‘aggressive’ cancer, she held little Scarlett close and promised to get matching wigs after the schoolgirl pleaded: “don’t lose your hair, you look beautiful.”

Melissa was diagnosed with breast cancer just over a month ago, and is now set to undergo treatment during England’s lockdown period.

Melissa is ready to take on treatment but worries losing her hair will affect her confidence

She said the length of the NHS waiting lists had forced her to go private for a diagnosis.

The solo mum is coping with her diagnosis by keeping up high spirits to buoy her daughter.

Desperate to stop Scarlett from worrying about her, they decided to name her tumour ‘Bugsley’ and are planning on co-ordinating their wigs while they get through this tough time.

Melissa said: “I found a lump on my breast and realised it could be cancer – but I was told the earliest mammogram I could have was in a month because I was only 40 and didn’t have any other symptoms.

“I didn’t want to take the risk so I ended up going private, and I’m so thankful I did. The scan found grade-3 invasive ductile cancer, so I could have been terminal by now if I’d waited a month.

The mum and daughter hope to get matching wigs

“I don’t blame the NHS at all because they don’t have the resources to give everyone the scans they need, so some people like me end up slipping through the net.

“If any good could come from this, I’d love it to raise awareness that it can happen to anyone. Ultimately they need to lower the age for quick mammograms and make sure everyone gets scanned early.

“Breaking the news to Scarlett was really hard, but I made sure to do it in a way she could understand.

“I told her mummy was poorly and I had to have some magic medicine. I said she shouldn’t be worried because the magic medicine would make mummy better.

“We called the tumour ‘Bugsley’, and after my operation I told her Bugsley was gone but I still have tiny little Bugsleys left and the medicine will make them go off into the wild.”

Melissa set up a GoFundMe page for a wig after Scarlett begged her to not lose her hair.

The page has raised more than £1,200 in less than a week – and Melissa has promised that her real hair will be donated to McMillan so kids can get their own wigs made.

The fundraising page, posted on October 28, said the breastcancer diagosis was a “shock” to her, as someone only

Read More